Conditions

By Guest Writer David Kliff, Diabetic Investor: As we were getting ready to disembark the plane when it arrived in Lisbon I asked a long-term consultant to the diabetes industry why he comes to EASD. “I like to come here because what they have here will show up in our country in two years” was his response. Given what we witnessed at EASD there isn’t much to look forward to in 2019.

Received a phone call from someone I know. Has not yet come in for a visit. Just called to see if she qualified to come in for a visit. Woman, 68 years of age, denies history of diabetes, hypertension or other health problems, except being overweight. She stated, “Last year my weight was up. I went on a diet because my triglycerides were high, in the 600’s, but they came down to 140’s when I lost 30 pounds last year. I think I gained back about 10 pounds so that would be about 155 pounds now.” I asked her if she’s weighed herself. She said, no, not since I got off the program, but when I was on the program, I weighed daily. You know, I had holidays, travel, I was with a group, paid for the food, so ate what they all ate, then I just couldn’t get back on track.”

Trial results promising, but DKA still a concern with use of new once-daily pills.

Philadelphia youth see rise in diagnosis; especially for African Americans, by 70%.

Common osteoarthritis treatment may be beneficial in lowering HbA1c.

Intensive control of blood pressure, glucose, and lipids benefits patients with type 2 diabetes, the long-awaited, large Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases (J-DOIT3).

The results of the REMOVAL study were presented at the 2017 European Association for the Study of Diabetes (EASD) in Lisbon

The investigational sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (Merck), being developed to improve glycemic control in adults with type 2 diabetes, met the primary outcomes in two yearlong phase 3 trials, VERTIS SU and VERTIS SITA2.

New study finds lower occurrence of heart failure in older people with type 2.

Real-time monitoring produces significant long-term improvement in HbA1c.